Lineage, Inc. LINE 深 滬
已收盤 01-09 16:00:00 美东时间
36.49
-0.060
-0.16%
華盛通- 最 高37.08
- 今 開36.71
- 成交量 87.11万股
- 最 低 35.70
- 昨 收 36.55
- 總市值 83.56亿
- 52周最高 60.19
- 市盈率 靜 --
- 換手率 0.38%
- 52周最低 31.9275
- 委 比 -95.90%
- 總股本 2.29亿
- 歷史最高 86.8325
- 量 比 0.84
- 振 幅 3.78%
- 歷史最低 31.9275
- 每 手 1
- 風險率 7.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
UBS Maintains Neutral on Lineage, Lowers Price Target to $35
UBS analyst Michael Goldsmith maintains Lineage (NASDAQ:LINE) with a Neutral and lowers the price target from $41 to $35.
01-09 02:36
Real estate stocks: What to expect in 2026
As widely expected, returns across real estate subsectors varied significantly in 2025. While the S&P 500 real estate sector ended the year in red against the broader S&P 500’s ~16% gain, health care ...
01-04 01:26
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
Lineage declares $0.5275 dividend
Lineage (LINE) declares $0.5275/share quarterly dividend, in line with previous. Forward yield 6.15% Payable Jan. 21; for shareholders of record Dec. 31; ex-div Dec. 31. See LINE Dividend Scorecard, Y...
2025-12-19 05:34
Baird Downgrades Lineage to Neutral, Lowers Price Target to $39
Baird analyst Nicholas Thillman downgrades Lineage (NASDAQ:LINE) from Outperform to Neutral and lowers the price target from $45 to $39.
2025-12-18 19:13
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
美股异动 | 今年美国最大IPO来袭 Medline(MDLN.US)上市首日开盘大涨超20%
周三，美国医疗巨头Medline(MDLN.US)登陆美股市场，开盘报35美元，涨幅超过20%，IPO价格为29美元。截至发稿，该股涨幅扩大至超25%，报36...
2025-12-17 23:59
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
Issued on behalf of Avant Technologies Inc. Equity Insider News Commentary VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- The cell therapy manufacturing sector reached a pivotal inflection poi...
2025-12-17 00:53
Shares of REITs are trading higher after the Fed cut rates, which could drive a rotation into dividend-paying sectors.
Shares of REITs are trading higher after the Fed cut rates, which could drive a...
2025-12-11 04:47
